Deamidated gliadin peptides

Detection of gliadin antibodies has been used for a long time in celiac disease diagnostics, but suffered from a low specificity. This disadvantage was overcome by the introduction of deamidated gliadin peptides as antigen.  

The ratio behind is that tissue transglutaminase catalyzes gliadin deamidation in the intestinal mucosa of celiac disease patients, resulting in deamidated gliadin peptides which are recognized by HLA receptors of immune cells. Therefore, deamidated gliadin antibodies are specific for celiac disease.

We introduced four different variations of deamidated gliadin antigens composed by a carrier protein linked with a combination of the deamidated 33-mer and 26-mer gamma gliadin peptides and the DQ2-GI- and DQ2-GII-peptides (Dørum S. et al., J Proteome Res. 2009; 8:1748-55).
In addition, the non-deamidated native versions as well as the carrier protein control are available (Section: Cereal Proteins).

deamidated gliadin peptides

Art. No.
G005 DGPx4
(Fusion protein of 4 deamidated gliadin peptides)
500 µg
735 €
G006 DGPx2
(Fusion protein of 2 deamidated gliadin peptides)
500 µg
735 €
G007 DGPx1
(deamidated gliadin peptide)
500 µg
735 €
G017 Biotinylated DGPx1 (deamidated gliadin peptide)
100 µg
370 €
G051 26mer gliadin peptide
(26mer-gamma gliadin peptide (aa 59-84) fused to carrier protein)
250 µg
370 €
G052 33mer gliadin peptide
(33mer-alpha gliadin peptide (aa 57-89) fused to carrier protein)
250 µg
370 €
G054 33mer DGP
(33mer-deamidated alpha gliadin peptide (aa 57-89) fused to carrier protein)
250 µg
370 €
G055 Carrier protein control
(Control for G051, G052, G054, G007, G006 and G005)
250 µg
370 €
G056 DGP and Gliadin peptides (Set No 1)
(G051, G052, G007, G054 and G055, 100 µg each)
1 Set
740 €


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • Zedira supports Gordon Research Conference
  • imagePress release: Zedira announces ISO 9001:2015 certification
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation



  • 19th International Celiac Disease Symposium

    14.10.2021 - 17.10.2021
    Sorrento, Italy

  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA